| Course | NR 546 Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner |
|---|---|
| Week | 8 |
| Paper type | Psychopharmacology case paper |
| Length | About 1,120 words, 2 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Psychiatric-Mental Health Nurse Practitioner (PMHNP) |
| Updated | September 2026 |
Free sample paper for NR 546 Week 8
Psychopharmacology Case Paper: One Teacher's First Episode of Depression With Anxious Distress, Carried From Target Symptoms Through Escitalopram Selection, Titration, a Stalled Response and a Sleep Study to the Six-Month Review
Student Name
College of Nursing, Chamberlain University
NR 546: Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
Instructor Name
Month Day, Year
Psychopharmacology Case Paper: One Teacher's First Episode of Depression With Anxious Distress, Carried From Target Symptoms Through Escitalopram Selection, Titration, a Stalled Response and a Sleep Study to the Six-Month Review
Patient and Target
A middle school science teacher, aged 41, presented with two months of low mood, constant worry about work, loss of interest in running and waking at 4 a.m. unable to return to sleep. The PHQ-9 was 18 and the GAD-7 was 13. Some days brought passing thoughts that being dead would be a relief; there was no plan, no intent and no prior attempt. Relevant history included diarrhea-predominant irritable bowel syndrome, migraines needing a triptan roughly twice monthly, ibuprofen now and then for the back, obesity (BMI 32), glucose in the prediabetic range (HbA1c 6.1%) and a previous three-week trial of fluoxetine at age 29, stopped for jitteriness and insomnia. The patient drank around two glasses of wine on most nights.
The treatment targets were fixed at the first visit in the patient's own terms: sleep through to 6 a.m., plan lessons without dread and run again. The measurable targets were a PHQ-9 below 5, indicating remission, and a GAD-7 below 5.
Formulation, as Far as It Constrains
The working diagnosis was a single major depressive episode of moderate to severe intensity, with the anxious distress specifier. Two diagnostic points constrained what could be prescribed. Screening found no history of hypomania, and no relative had bipolar disorder, which made an antidepressant alone appropriate. And the anxious distress specifier weighed on the choice of agent, since anxiety symptoms can be aggravated by activating drugs. Thyroid function was normal.
Selection With Its Alternative
Building on that formulation, escitalopram was chosen. Average efficacy differs little among newer antidepressants, so the choice rested on this patient's factors (Cipriani et al., 2018). Sertraline, a close alternative, was set aside because of its tendency to loosen stools in a patient with diarrhea-predominant irritable bowel syndrome. Bupropion, attractive for its low rate of sexual dysfunction (Serretti & Chiesa, 2009) and weight neutrality, was set aside because of the anxious distress, where a pooled analysis found a modest advantage for serotonin reuptake inhibitors (Papakostas et al., 2008), and because of the patient's previous activation on fluoxetine. Mirtazapine was set aside because its histamine blockade commonly causes weight gain in a patient with prediabetes.
Dose and Titration
Taking the patient's sensitivity to activation and the bowel condition from the selection, escitalopram began at 5 mg daily for seven days, below the usual 10 mg, then increased to 10 mg. The written plan called for 20 mg from week 6 if the PHQ-9 had improved by less than 50%, after four weeks at 10 mg, because benefit from these drugs builds over several weeks (Taylor et al., 2006). The ceiling was 20 mg.
Monitoring on the Schedule
Monitoring followed the titration points: a phone contact at two weeks and visits at weeks 4, 6, 8 and 12, each with PHQ-9, GAD-7, a suicide screen, weight, sexual function and adherence. A safety plan was in place from the first visit. The adverse effects chosen for counseling were those likely to end treatment in this patient, gastrointestinal upset, sexual dysfunction, sleep change and discontinuation symptoms, and those serious enough to warrant specific warnings given the patient's other medicines: bleeding with ibuprofen (Laporte et al., 2017) and serotonin toxicity with sumatriptan. The latter combination was continued with counseling because the risk in a large coprescription study was very low (Orlova et al., 2018).
The Course
By week 4 the PHQ-9 was 14, with early nausea settled and mild delayed orgasm. At week 6 the PHQ-9 was 12, a 33% improvement, and the plan called for 20 mg. The patient asked to wait, concerned about side effects, and the dose stayed at 10 mg. By week 10 the PHQ-9 was 11 and had stalled. Mood and worry had improved, but fatigue, poor concentration and unrefreshing sleep persisted.
The analysis at that point tested the ordinary explanations before changing the drug. The dose was below the planned level. The patient was missing about two doses a week on rushed mornings. Evening alcohol was unchanged. And new history, loud snoring with observed pauses in breathing, an Epworth score of 13 and a body mass index of 32, suggested obstructive sleep apnea, which is associated with the development of depression (Peppard et al., 2006) and could account for the residual fatigue.
The response was tied to each explanation: the dose moved to the evening with a pill organizer; after two weeks of consistent dosing, escitalopram increased to 20 mg; a sleep study was ordered; and the patient agreed to no alcohol on work nights. In a large sequential treatment study, many patients who did not remit at first reached remission after adequate dosing and further steps (Rush et al., 2006), which supported persisting with an optimized first step before switching.
The Review Point
The review at week 16 tested each part of the reasoning. Adherence: the patient reported one missed dose in four weeks. Dose: 20 mg was tolerated; loose stools increased briefly and settled, and delayed orgasm was unchanged, which the patient found acceptable. Sleep: the sleep study showed moderate obstructive sleep apnea, and the patient had started continuous positive airway pressure three weeks earlier. Alcohol: work-night drinking had stopped. Scores: PHQ-9 was 5 and GAD-7 was 4. The patient was running twice a week.
The PHQ-9 of 5 is at the threshold of remission, not clearly below it. The next review is at week 24. The plan is to continue escitalopram 20 mg for six to nine months or longer once remission is confirmed, since early stopping raises relapse risk, and to review the effect of sleep treatment. If remission is not reached by week 24 despite treated sleep apnea and full adherence, adding bupropion would be the next step, chosen partly because it might also relieve the sexual side effect.
What Remains Uncertain
It is not possible to separate how much of the improvement came from the dose increase, better adherence, treated sleep apnea or reduced alcohol, since all changed within a few weeks. That was a deliberate trade-off: waiting to change one factor at a time would have left the patient symptomatic longer. The uncertainty matters for the future. If depression recurs, the sleep apnea treatment and alcohol use should be reviewed before assuming the medicine has failed.
References
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., Egger, M., Takeshima, N., Hayasaka, Y., Imai, H., Shinohara, K., Tajika, A., Ioannidis, J. P. A., & Geddes, J. R. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357-1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Laporte, S., Chapelle, C., Caillet, P., Beyens, M.-N., Bellet, F., Delavenne, X., Mismetti, P., & Bertoletti, L. (2017). Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacological Research, 118, 19-32. https://doi.org/10.1016/j.phrs.2016.08.017
Orlova, Y., Rizzoli, P., & Loder, E. (2018). Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurology, 75(5), 566-572. https://doi.org/10.1001/jamaneurol.2017.5144
Papakostas, G. I., Stahl, S. M., Krishen, A., Seifert, C. A., Tucker, V. L., Goodale, E. P., & Fava, M. (2008). Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): A pooled analysis of 10 studies. Journal of Clinical Psychiatry, 69(8), 1287-1292. https://doi.org/10.4088/JCP.v69n0812
Peppard, P. E., Szklo-Coxe, M., Hla, K. M., & Young, T. (2006). Longitudinal association of sleep-related breathing disorder and depression. Archives of Internal Medicine, 166(16), 1709-1715. https://doi.org/10.1001/archinte.166.16.1709
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917. https://doi.org/10.1176/ajp.2006.163.11.1905
Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. Journal of Clinical Psychopharmacology, 29(3), 259-266. https://doi.org/10.1097/JCP.0b013e3181a5233f
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006). Early onset of selective serotonin reuptake inhibitor antidepressant action: Systematic review and meta-analysis. Archives of General Psychiatry, 63(11), 1217-1223. https://doi.org/10.1001/archpsyc.63.11.1217
What the NR 546 Week 8 assignment asks for
The final week asks for a comprehensive psychopharmacology case paper. Typical instructions request the presentation and target symptoms, diagnostic formulation, medication selection with rationale and alternatives, dosing and titration, monitoring, response and adjustments, and a plan for continuation, with current evidence. Open with the patient and specific, measurable targets. Keep the formulation to what constrains prescribing, such as bipolar screening or a specifier that affects drug choice. Defend the chosen agent against its alternatives using patient factors. Justify the dose and schedule. Put monitoring on dates. Describe the course, including any setback, and how it was analyzed. End at a review point that tests the targets, and state what remains uncertain. Let each section build on the one before. Place citations beside claims in APA 7.
Inside the NR 546 Week 8 example
The paper opens with the presentation, history and targets in the patient's words and as scores. The formulation section notes negative bipolar screening and the anxious distress specifier. The selection section defends escitalopram against sertraline, bupropion and mirtazapine with evidence. The dosing and monitoring sections set the lower first week, the planned increase and scheduled checks, including interaction counseling. The course section follows the scores to a stall at week 10 and summarizes the analysis: dose below plan, missed doses, evening alcohol and probable sleep apnea. The review at week 16 finds good adherence, tolerated 20 mg, confirmed and treated sleep apnea and a PHQ-9 of 5. The paper closes with continuation plans and the uncertainty about which change helped most.
NR 546 Week 8 rubric: what full points look like
Case papers are generally judged on a clear presentation and targets, a focused formulation, well-defended selection, justified dosing and monitoring, thoughtful handling of the course and a continuation plan, with scholarly writing. A paper in which each section depends on the one before reads as one argument, which is what separates it from a set of assignments. Measurable targets give the review point something to test. Defending the choice against alternatives with patient factors shows judgment. Handling a setback by testing explanations before switching shows mature prescribing. An honest statement of uncertainty strengthens credibility. Citations placed beside claims, current and formatted in APA 7, and a consistent patient throughout complete the expectations.
NR 546 Week 8 help: mistakes that cost points
Final papers often read as earlier assignments pasted together, with repeated background and no connection between sections. Rewrite so each part builds on the last. Another weakness is a formulation that becomes a diagnostic essay; keep it to what affects prescribing. Some students present the course as a smooth success, which misses the chance to show how they handle a setback. Include what went wrong and how it was analyzed. Avoid vague targets that cannot be checked at review. Keep the patient's details consistent across sections. Do not cluster citations in the introduction. End with a clear continuation plan and an honest note of what is still uncertain, since that is expected at this level and signals careful reasoning.
Get a NR 546 Week 8 example written to your instructions
Send the Week 8 instructions with the required element list and the case your section supplies, and a custom example is written to those requirements and returned inside 24 to 48 hours. The first one is free. The case you carry through your own term stays yours to argue.
More NR 546 papers and PMHNP samples
- NR 546 Week 1: Antidepressant Timing Discussion
- NR 546 Week 2: Receptor Mechanism Write-Up
- NR 546 Week 3: Medication Selection Rationale
- NR 546 Week 4: Titration and Monitoring Plan
- NR 546 Week 5: Partial Response Case Analysis
- NR 546 Week 6: Adverse Effect Brief
- NR 546 Week 7: Medication Education Handout
NR 546 Week 8 questions, answered
Can I reuse my earlier assignments in this paper?
Check your section, since some allow it and some treat it as self-plagiarism requiring citation. Even where it is allowed, the material usually needs rewriting rather than pasting, because the paper has to run as one argument. The clearest sign of assembly is a patient who acquires or loses details between sections.
How much diagnostic reasoning belongs in a pharmacology paper?
Only as much as constrains the prescribing. A comorbidity that rules out an agent, a symptom that decides the target, a history that changes the starting dose all belong. A full diagnostic formulation does not, and papers that supply one usually run out of length before the monitoring section, which is where the pharmacology marks actually sit.
What if I am not certain about part of the plan?
Say so, and say what would resolve it. Naming the uncertainty and the information that would settle it reads as judgment at this level. What loses marks is a paper written with uniform confidence throughout, because a reader who knows the material can see which claims were not actually supported by what the case provided.
Where can I find a free NR 546 Week 8 sample paper?
The escitalopram case paper from target symptoms to review is displayed above as the NR 546 Week 8 sample, completely visible. For a different final patient, share the history and targets with our writers and they can draft a case paper built as one argument.
How should the NR 546 Week 8 paper handle setbacks?
Show the setback and how it was analyzed before any change. The sample describes a stall at week 10, traces it to dose, adherence, alcohol and sleep apnea and follows the fix to a PHQ-9 of 5.